CFO
ADMA icon

CVA Family Office’s ADMA Biologics ADMA Stock Holding History

CVA Family Office’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$640 Buy
+71
New +$1.12K ﹤0.01% 1717

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

CVA Family Office's ADMA Position: Q1 2026 in Review

CVA Family Office opened a new position in ADMA Biologics (ADMA) in Q1 2026: 71 shares worth $640. The stake represents ﹤0.01% of the portfolio and ranks #1717 among its holdings.

356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • CVA Family Office held 71 shares of ADMA Biologics worth $640 as of Q1 2026.
  • ADMA Biologics was a new CVA Family Office position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1717 holding.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.